Takeda submits new drug application to manufacture and market darvadstrocel in japan for treatment of complex perianal fistulas in adult patients with crohn's disease

Osaka, japan--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced that it has submitted an application to the japanese ministry of health, labour and welfare to manufacture and market darvadstrocel (development code: cx601) for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal crohn's disease (cd). the application filing included data from two trials, the japanese study darvadstrocel-3002 and the
TAK Ratings Summary
TAK Quant Ranking